Short answer
Atrium Therapeutics, Inc. (RNA) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $15M with net income of −$4M.
Q3 2026 key financials · XBRL
- Revenue
- $15M
- +410.0% QoQ
- Net income
- −$4M
- +78.9% QoQ
- Operating margin
- -43.3%
- EPS (diluted)
- −$0.26
- +78.0% QoQ
Source: XBRL data from the Atrium Therapeutics, Inc. (RNA) Q3 2026 10-Q on SEC EDGAR. USD.
Atrium Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $15.3M, up $3.0M YoY, driven by a $15.0M BMS milestone
- Net loss $4.3M vs $0.0M YoY, with operating expenses $22.0M vs $12.6M
- Best program: ATR 1086 R&D spending $3.1M, up from $2.1M YoY
- Operating cash outflow $60.4M, cash and equivalents $44.6M, short-term investments $187.5M
- October PIPE generated $46.5M net proceeds, with proof-of-concept data anticipated in second half of 2027
Risk Factors
- Newly added financing risk: October 2026 Offering sold 5,170,384 shares and warrants, diluting existing stockholders
- Most material regulatory update: FDA cleared ATR 1072 IND in July 2026, but leadership changes may increase development uncertainty
- Compliance exposure: Federal Anti-Kickback Statute and False Claims Act violations could trigger civil or criminal penalties
- Near-term execution risk: First Corventis Phase 1/2 patient dosed in October 2026, with rare cardiac populations complicating enrollment
- Liquidity risk: $44.6 million cash and $187.5 million short-term investments fund operations for at least 12 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Atrium Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.